MX2018010132A - Inhibidores peptidicos de los canales de calcio. - Google Patents

Inhibidores peptidicos de los canales de calcio.

Info

Publication number
MX2018010132A
MX2018010132A MX2018010132A MX2018010132A MX2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A
Authority
MX
Mexico
Prior art keywords
calcium channels
calcium
peptide inhibitors
calcium influx
channels
Prior art date
Application number
MX2018010132A
Other languages
English (en)
Spanish (es)
Inventor
Tarran Robert
Wu Tongde
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2018010132A publication Critical patent/MX2018010132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2018010132A 2016-02-22 2017-02-22 Inhibidores peptidicos de los canales de calcio. MX2018010132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298204P 2016-02-22 2016-02-22
PCT/US2017/018840 WO2017147128A1 (en) 2016-02-22 2017-02-22 Peptide inhibitors of calcium channels

Publications (1)

Publication Number Publication Date
MX2018010132A true MX2018010132A (es) 2019-06-06

Family

ID=59685595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010132A MX2018010132A (es) 2016-02-22 2017-02-22 Inhibidores peptidicos de los canales de calcio.

Country Status (9)

Country Link
US (1) US10894811B2 (enExample)
EP (1) EP3419994B1 (enExample)
JP (1) JP2019512216A (enExample)
AU (1) AU2017222450A1 (enExample)
BR (1) BR112018017144A2 (enExample)
ES (1) ES2979122T3 (enExample)
IL (1) IL261265A (enExample)
MX (1) MX2018010132A (enExample)
WO (1) WO2017147128A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3554527A1 (en) * 2016-12-13 2019-10-23 Spyryx Biosciences, Inc. Saline formulations of splunc1 peptides
WO2022204185A1 (en) * 2021-03-22 2022-09-29 The University Of North Carolina At Chapel Hill Modified peptidomimetics and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
CA2271325A1 (en) 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
ATE255229T1 (de) * 2000-02-24 2003-12-15 Oxford Glycosciences Uk Ltd Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
US20050192221A1 (en) * 2003-12-04 2005-09-01 Mccray Paul B.Jr. Methods and compositions related to plunc polypeptides
DE102004031579B4 (de) * 2004-06-29 2012-12-27 Forschungsverbund Berlin E.V. Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung
BR112014006535A2 (pt) * 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc

Also Published As

Publication number Publication date
US10894811B2 (en) 2021-01-19
BR112018017144A2 (pt) 2019-01-15
ES2979122T3 (es) 2024-09-24
EP3419994B1 (en) 2024-05-08
AU2017222450A1 (en) 2018-09-27
JP2019512216A (ja) 2019-05-16
IL261265A (en) 2018-10-31
EP3419994A1 (en) 2019-01-02
EP3419994C0 (en) 2024-05-08
EP3419994A4 (en) 2019-11-06
US20190062386A1 (en) 2019-02-28
WO2017147128A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
ZA202502749B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
EA033325B1 (ru) Ингибиторы бромодомена
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
MY200933A (en) Biparatopic Polypeptides Antagonizing Wnt Signaling In Tumor Cells
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2020000611A (es) Composiciones y metodos para tratar trastornos relacionados con el estres.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
WO2018125799A3 (en) Metalloenzyme inhibitor compounds
PH12017500613A1 (en) Improved peptide inhibitors of sodium channels
GB2574747A (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
BR112018017144A2 (pt) inibidores de peptídeo de canais de cálcio
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.